How Will Elanco's Integration Shape the Cattle Sector?
GLOBAL - Two major animal health players integrated last month - but what does this mean for the cattle health?
12 February 2015
1 minute read
According to Elanco's President of North American Operations, Rob Auckerman, Elanco's acquisition of Novartis gives the company a "much more global footprint", broadening its portfolio and allowing ventures into new areas and consolidation in familiar fields.
This will mean increased innovation, services and technical support.
New projects in enzymes, aquaculture and diagnostics will come, as will wider range in vaccines, therapuetics, parasiticides and food safety solutions, Mr Auckerman told TheCattleSite.
"We will have a strong presence in every segment, in every species around the world - a much stronger global presence and much broader portfolio," he said. "We have a lot of major projects in the pipeline. There are over one hundred development projects that we are focussed on."
He pointed to future expansion in analytics and benchmarking, highlighting the role of data in sustainable businesses.
"If we improve the productivity and efficiency of operations, that is contributing to sustainbility and utilizing a lot less resources and inputs for the same output."
